HPBCD is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease
Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin
A forum for researchers, students and applicants in the field of cyclodextrin technology
Niemann-Pick type C1 (NPC1) disease is a fatal neurovisceral disease for which there are no FDA approved treatments, though cyclodextrin